Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

PURPOSE: Dasatinib inhibits src family kinases and has anti-angiogenic properties. We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC). METHODS: Patients were enrolled in a dose esc...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Strickler, John H., McCall, Shannon, Nixon, Andrew B., Brady, John C., Pang, Herbert, Rushing, Christel, Cohn, Allen, Starodub, Alexander, Arrowood, Christy, Haley, Sherri, Meadows, Kellen L., Morse, Michael A., Uronis, Hope E., Blobe, Gerard C., Hsu, S. David, Zafar, S. Yousuf, Hurwitz, Herbert I.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2013
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4108590/
https://ncbi.nlm.nih.gov/pubmed/24173967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0042-9
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة